Welcome to our dedicated page for Ryan Specialty Hldgs SEC filings (Ticker: RYAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ryan Specialty Holdings, Inc. (NYSE: RYAN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Ryan Specialty is an international specialty insurance firm that serves insurance brokers, agents, and carriers through distribution, underwriting, product development, administration, and risk management services, and its filings offer detailed insight into how this business is structured and performs.
Investors can review current reports on Form 8-K, where Ryan Specialty discloses material events. Recent 8-K filings have covered topics such as quarterly financial results and the associated earnings press releases, regular quarterly dividends on Class A common stock, appointments and retirements of directors, and changes in executive roles, including the appointment of Co-Presidents and related governance matters. These filings often incorporate press releases by reference, providing context for operational and governance decisions.
In addition to 8-Ks, users can access Ryan Specialty’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which contain comprehensive financial statements, segment information for specialties such as Wholesale Brokerage, Binding Authority, and Underwriting Management, and discussions of non-GAAP measures like Organic Revenue Growth Rate, Adjusted EBITDAC, and Adjusted net income. These documents also include risk factor discussions and other disclosures relevant to the specialty insurance business.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers understand revenue composition, expense ratios, non-GAAP metrics, and governance changes without reading every page. The platform updates in near real time as new RYAN filings are posted to EDGAR, and also surfaces information related to dividends and board decisions. For users researching RYAN stock, this filings hub offers a structured way to analyze Ryan Specialty’s regulatory history and ongoing reporting obligations.
Ryan Specialty Holdings, Inc. director and Chief Executive Officer Timothy William Turner received a grant of 168,577 Executive Chairman stock options. The options have an exercise price of $29.66 per share, expire on May 5, 2036, and are exercisable on a 1-for-1 basis into Class A common stock. They vest in equal installments on July 1, 2029, July 1, 2030, and July 1, 2031, and were approved by the board’s compensation and governance committee.
RYAN SPECIALTY HOLDINGS, INC. Co-President and CRO Brendan Martin Mulshine received a grant of 33,715 Executive Chairman stock options linked to Class A common stock. The options have a $29.66 per-share exercise price and expire on May 5, 2036.
These options vest in three equal installments on July 1, 2029, 2030 and 2031, and are exercisable on a 1-for-1 basis for Class A common shares. Following this grant, Mulshine holds 33,715 derivative securities directly. The grant was approved by the issuer’s compensation and governance committee for purposes of Rule 16(b)(3).
KATZ MARK STEPHEN reported acquisition or exercise transactions in this Form 4 filing.
Ryan Specialty Holdings reported that EVP & General Counsel Mark Stephen Katz received a grant of 33,715 Executive Chairman stock options on May 5, 2026. The options have a strike price of $29.66, vest in three equal parts on July 1 of 2029, 2030 and 2031, and expire on May 5, 2036. Following this award, he holds 33,715 options, each exercisable into one share of Class A common stock.
RYAN Specialty Holdings CEO Benjamin Miles Wuller received a grant of 33,715 Executive Chairman stock options as equity compensation. The options have an exercise price of $29.66 per share and are exercisable on a 1-for-1 basis into Class A common stock.
The options vest in equal installments on July 1 of 2029, 2030, and 2031 and expire on May 5, 2036. The grant was approved by the issuer’s compensation and governance committee for purposes of Rule 16(b)(3), and it is not an open-market share purchase.
RYAN SPECIALTY HOLDINGS, INC. reported that Chief Financial Officer Janice M. Hamilton received a grant of stock options tied to the company’s Class A common stock. The award covers 33,715 options with an exercise price of $29.66 per share and no cash changed hands at grant.
The options vest in three equal installments on July 1 of 2029, 2030 and 2031, and expire on May 5, 2036. Once vested, each option can be exercised on a 1-for-1 basis for one share of Class A common stock. This appears to be a routine compensation-related equity grant approved by the board’s compensation and governance committee.
RYAN SPECIALTY HOLDINGS, INC. disclosed that Executive Chairman Patrick G. Ryan, acting as trustee of the Ryan Stock Option Trust, entered into an Executive Chairman Option Settlement Agreement with the company. Under this agreement, the trust is obligated to sell to the company up to 1,787,446 shares of Class A common stock over time.
The company may purchase these shares at an exercise price of $29.66 per share through June 10, 2036, as related employee stock options vest and are exercised in 2029, 2030 and 2031 under the 2021 Omnibus Incentive Plan. The Form 4 records this as an indirect derivative disposition to the issuer by the trust.
Ryan Specialty Holdings, Inc. reported the results of its annual stockholder meeting. All director nominees were elected to serve until the 2027 annual meeting, with each receiving over 1.22 billion votes in favor and relatively few votes against or withheld.
Stockholders also approved the ratification of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 1,245,571,118 votes in favor. In addition, the advisory proposal on executive compensation passed, receiving 1,235,002,019 votes for, 202,513 against, and 52,630 abstentions, along with 10,447,967 broker non-votes.
Ryan Specialty Holdings reported solid growth for the quarter ended March 31, 2026. Total revenue rose to $795.2 million, driven mainly by net commissions and fees of $782.9 million, up from $676.1 million a year earlier. Net income was $40.6 million, compared with a net loss of $4.4 million in the prior-year quarter, and diluted earnings per Class A share improved to $0.13 from a loss of $0.22.
The company remains highly leveraged, with total debt of about $3.57 billion and significant use of its $1.4 billion revolving credit facility. It launched the Empower restructuring program, expecting total costs of $160 million through 2028 and projected annual savings of about $80 million in 2029. During the quarter, Ryan Specialty repurchased 982,073 Class A shares for roughly $40 million and paid a regular quarterly cash dividend of $0.13 per Class A share.
RYAN PATRICK G JR reported acquisition or exercise transactions in this Form 4 filing.
Ryan Specialty Holdings, Inc. director Ryan Patrick G Jr reported an equity award of 5,757 shares of Class A Common Stock, delivered as Restricted Stock Units that vested immediately upon grant. The grant carried a per-share price of $0.00, reflecting compensation rather than a market purchase.
Following the award, he directly owns 262,316.053 Class A shares. In addition, 428,295 Class A shares are held in trusts for his and/or family members’ benefit, where he serves as trustee and disclaims beneficial ownership except for his pecuniary interest. The grant was approved by the Board for purposes of Rule 16(b)(3).
ROGERS JOHN W JR reported acquisition or exercise transactions in this Form 4 filing.
Ryan Specialty Holdings director John W. Rogers Jr. received an award of 5,757 shares of Class A Common Stock in the form of Restricted Stock Units that vested immediately upon grant. He elected to defer settlement of these units until his separation from the board of directors, consistent with the company’s director compensation program.
Following this award, he directly holds or has deferred rights tied to a total of 110,433 shares, which includes 15,270 previously granted Restricted Stock Units that also vested immediately upon grant and are similarly deferred until he leaves board service.